

Title (en)
NEURAL REGENERATION PEPTIDES AND METHODS FOR THEIR USE IN TREATMENT OF BRAIN DAMAGE

Title (de)
PEPTIDE FÜR DIE REGENERATION VON NERVEN UND VERFAHREN ZU DEREN ANWENDUNG BEI DER BEHANDLUNG VON HIRNSCHÄDEN

Title (fr)
REGENERATION NEURONALE DE PEPTIDES ET METHODES D'UTILISATION DANS LE TRAITEMENT DES TROUBLES CEREBRAUX

Publication
EP 1685151 A4 20090422 (EN)

Application
EP 04800514 A 20041101

Priority

- US 2004036203 W 20041101
- US 51601803 P 20031031
- US 58504104 P 20040702
- US 61627104 P 20041005

Abstract (en)
[origin: WO2005042561A2] The invention discloses a family of peptides termed NRP compounds or NRPs that can promote neuronal migration, neurite outgrowth, neuronal proliferation, neural differentiation and/or neuronal survival, and provides compositions and methods for the use of NRPs in the treatment of brain injury and neurodegenerative disease. NRP compounds can induce neurons and neuroblasts to proliferate and migrate into areas of damage caused by acute brain injury or chronic neurodegenerative disease, such as exposure to toxins, stroke, trauma, nervous system infections, demyelinating diseases, dementias, and metabolic disorders. NRP compounds may be administered directly to a subject or to a subject's cells by a variety of means including orally, intraperitoneally, intravascularly, and directly into the nervous system of a patient. NRP compounds can be formulated into pharmaceutically acceptable dose forms for therapeutic use. Methods for detecting neural regeneration, neural proliferation, neural differentiation, neurite outgrowth and neural survival can be used to develop other neurally active agents.

IPC 8 full level
A01N 61/00 (2006.01); **A01N 37/18** (2006.01); **A61K 35/30** (2015.01); **A61K 35/76** (2015.01); **A61K 38/16** (2006.01); **C07K 1/00** (2006.01); **C07K 14/475** (2006.01); **C12N 5/07** (2010.01); **C12N 5/079** (2010.01); **C12N 5/0793** (2010.01); **C12N 5/0797** (2010.01)

IPC 8 main group level
C07K (2006.01)

CPC (source: EP)
A61P 1/16 (2018.01); **A61P 3/00** (2018.01); **A61P 3/08** (2018.01); **A61P 9/04** (2018.01); **A61P 9/10** (2018.01); **A61P 9/12** (2018.01); **A61P 17/02** (2018.01); **A61P 19/00** (2018.01); **A61P 21/00** (2018.01); **A61P 25/00** (2018.01); **A61P 25/02** (2018.01); **A61P 25/14** (2018.01); **A61P 25/16** (2018.01); **A61P 25/28** (2018.01); **A61P 25/30** (2018.01); **A61P 31/00** (2018.01); **A61P 35/00** (2018.01); **C07K 14/4756** (2013.01)

Citation (search report)
[A] WO 03018754 A2 20030306 - NEURONZ LTD [NZ], et al

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LU MC NL PL PT RO SE SI SK TR

DOCDB simple family (publication)
WO 2005042561 A2 20050512; **WO 2005042561 A3 20061012**; EP 1685151 A2 20060802; EP 1685151 A4 20090422; JP 2007511210 A 20070510; JP 5026083 B2 20120912

DOCDB simple family (application)
US 2004036203 W 20041101; EP 04800514 A 20041101; JP 2006538375 A 20041101